Once-Weekly Semaglutide in Adults with Overweight or Obesity

  • Javor, Eugen M.Pharm.
  • Lucijanić, Marko M.D., Ph.D.
  • Skelin, Marko Ph.D.

  • 1General Hospital Bjelovar, Bjelovar, Croatia [email protected]

    2Dubrava University Hospital, Zagreb, Croatia

    3University of Rijeka, Rijeka, Croatia

No potential conflict of interest relevant to this letter was reported.

Dr. Srivastava reports receiving consulting fees from Novo Nordisk and Rhythm Pharmaceuticals. Dr. Kumar reports receiving lecture fees from Novo Nordisk and Janssen Pharmaceuticals, receiving consulting fees from Gelesis, Pfizer, and Eli Lilly, and having an equity interest in Vivus. No other potential conflict of interest relevant to this letter was reported.

New England Journal of Medicine 385(1):p e4(1), July 1, 2021. | DOI: 10.1056/NEJMc2106918

Once-Weekly Semaglutide in Adults with Overweight or Obesity

  • Wilding, John P.H. D.M.
  • Batterham, Rachel L. M.B., B.S., Ph.D.
  • Calanna, Salvatore Ph.D.
  • Davies, Melanie M.D.
  • Van Gaal, Luc F. M.D., Ph.D.
  • Lingvay, Ildiko M.D., M.P.H., M.S.C.S.
  • McGowan, Barbara M. M.D., Ph.D.
  • Rosenstock, Julio M.D.
  • Tran, Marie T.D. M.D., Ph.D.
  • Wadden, Thomas A. Ph.D.
  • Wharton, Sean M.D., Pharm.D.
  • Yokote, Koutaro M.D., Ph.D.
  • Zeuthen, Niels M.Sc.
  • Kushner, Robert F. M.D.
New England Journal of Medicine 384(11):p 989-1002, March 18, 2021. | DOI: 10.1056/NEJMoa2032183

Corresponding Article

STEP 1 for Effective Weight Control — Another First Step?

  • Ingelfinger, Julie R. M.D.
  • Rosen, Clifford J. M.D.
New England Journal of Medicine 384(11):p 1066-1067, March 18, 2021. | DOI: 10.1056/NEJMe2101705
Copyright © 2021 Massachusetts Medical Society. All rights reserved.